Patent ID: 6043389
Filing Date: 2000-03-28
Classification: A61P,C07C

Abstract:
A compound represented by the formula: ##STR16## wherein R is C.sub.1 to C.sub.10 alkyl, C.sub.2 to C.sub.10 alkenyl or C.sub.2 to C.sub.10 alkynyl, optionally substituted with hydroxy, alkoxy, halo, trifluoromethyl, aryl or heteroaryl;R.sup.1 and R.sup.2 are independently H, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, or C.sub.2 -C.sub.10 alkynyl, any of which can be optionally substituted with halo, alkoxy, amino, trifluoromethyl, aryl or heteroaryl;R.sup.3 is(1) C.sub.1 -C.sub.12 alkyl or C.sub.2 -C.sub.10 alkenyl substituted with from one to ten substituents selected from the group consisting of hydroxy, alkoxy, acyloxy, and aroyloxy, and, optionally having one or more halo groups, wherein adjacent hydroxy groups, if present, can optionally be present as an acetonide,(2) --(CH.sub.2).sub.n -[O--(CH.sub.2).sub.p ].sub.m -OR.sup.4,(3) --(CH.sub.2).sub.n -PEG-OR.sup.4, or(4) --(CH.sub.2).sub.n -PPG-OR.sup.4 ;R.sup.4 is C.sub.1 to C.sub.6 alkyl, C.sub.2 to C.sub.6 alkenyl, aryl, acyl, aroyl, alkoxycarbonyl, aminocarbonyl or ##STR17## PEG is a polyethylene glycol moiety having an average molecular weight of 200-8000;PPG is a polypropylene glycol moiety having an average molecular weight of 200-8000;p is 2 to 4;n is 1 to 5;m is 1 to 6; ora pharmaceutically-acceptable salt thereof;with the proviso that when R is alkyl, R.sup.3 can not be monohydroxy-n-propyl.